Evidence map›Paper›PMID 32894144›Full record

ArticleMolecular cancer2020

Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.

Jiacheng Lou, Yuchao Hao, Kefeng Lin, Yizhu Lyu, Meiwei Chen, Han Wang, Deyu Zou, Xuewen Jiang, Renchun Wang, Di Jin and 8 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 3 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 3 syntheses or guidelines pooled it, 244 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. LncPTEN1, a long non-coding RNA generated fromNon-coding RNA research · 2025
    Article
  13. Article
  14. Article
  15. Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review.Apoptosis : an international journal on programmed cell death · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025
    Review

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Jiacheng LouDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Yuchao HaoDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Kefeng LinDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Yizhu LyuDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Meiwei ChenDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Han WangDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Deyu ZouDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Xuewen JiangDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Renchun WangThe Second Clinical Medicine School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.
Di JinDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Eric W-F LamDepartment of Surgery and Cancer, Imperial College London, W12 0NN, London, UK.
Shujuan ShaoDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Quentin LiuDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Jinsong YanDepartment of Hematology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China. yanjsdmu@126.com.
Xiang WangDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China.
Puxiang ChenDepartment of Obstetrics and Gynecology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China. 503157@csu.edu.cn.
Bo ZhangDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China. zhangbodl@126.com.
Bilian JinDepartment of Neurosurgery, The Second Affiliated Hospital; Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China. bjinmcg@outlook.com.ORCID 0000-0002-0852-9115
Dalian Medical University · CNCentral South University · CNImperial College London · GBJinan University · CNLanzhou University · CN

Funding

Cancer Research UK C37/18784Cancer Research UK C37/A12011Medical Research Council MR/N012097/1
6 · The paper itself

Abstract

backgroundInactivation of the tumor suppressor p53 is critical for pathogenesis of glioma, in particular glioblastoma multiforme (GBM). MDM2, the main negative regulator of p53, binds to and forms a stable complex with p53 to regulate its activity. Hitherto, it is unclear whether the stability of the p53/MDM2 complex is affected by lncRNAs, in particular circular RNAs that are usually abundant and conserved, and frequently implicated in different oncogenic processes.

methodsRIP-seq and RIP-qPCR assays were performed to determine the most enriched lncRNAs (including circular RNAs) bound by p53, followed by bioinformatic assays to estimate the relevance of their expression with p53 signaling and gliomagenesis. Subsequently, the clinical significance of CDR1as was evaluated in the largest cohort of Chinese glioma patients from CGGA (n = 325), and its expression in human glioma tissues was further evaluated by RNA FISH and RT-qPCR, respectively. Assays combining RNA FISH with protein immunofluorescence were performed to determine co-localization of CDR1as and p53, followed by CHIRP assays to confirm RNA-protein interaction. Immunoblot assays were carried out to evaluate protein expression, p53/MDM2 interaction and p53 ubiquitination in cells in which CDR1as expression was manipulated. After AGO2 or Dicer was knocked-down to inhibit miRNA biogenesis, effects of CDR1as on p53 expression, stability and activity were determined by immunoblot, RT-qPCR and luciferase reporter assays. Meanwhile, impacts of CDR1as on DNA damage were evaluated by flow cytometric assays and immunohistochemistry. Tumorigenicity assays were performed to determine the effects of CDR1as on colony formation, cell proliferation, the cell cycle and apoptosis (in vitro), and on tumor volume/weight and survival of nude mice xenografted with GBM cells (in vivo).

resultsCDR1as is found to bind to p53 protein. CDR1as expression decreases with increasing glioma grade and it is a reliable independent predictor of overall survival in glioma, particularly in GBM. Through a mechanism independent of acting as a miRNA sponge, CDR1as stabilizes p53 protein by preventing it from ubiquitination. CDR1as directly interacts with the p53 DBD domain that is essential for MDM2 binding, thus disrupting the p53/MDM2 complex formation. Induced upon DNA damage, CDR1as may preserve p53 function and protect cells from DNA damage. Significantly, CDR1as inhibits tumor growth in vitro and in vivo, but has little impact in cells where p53 is absent or mutated.

conclusionsRather than acting as a miRNA sponge, CDR1as functions as a tumor suppressor through binding directly to p53 at its DBD region to restrict MDM2 interaction. Thus, CDR1as binding disrupts the p53/MDM2 complex to prevent p53 from ubiquitination and degradation. CDR1as may also sense DNA damage signals and form a protective complex with p53 to preserve p53 function. Therefore, CDR1as depletion may play a potent role in promoting tumorigenesis through down-regulating p53 expression in glioma. Our results broaden further our understanding of the roles and mechanism of action of circular RNAs in general and CDR1as in particular, and can potentially open up novel therapeutic avenues for effective glioma treatment.

Indexed as

AnimalsApoptosisCarcinogenesisCell Line, TumorCell ProliferationDNA DamageGene Expression Regulation, NeoplasticGlioblastomaHumansMiceProto-Oncogene Proteins c-mdm2RNA, CircularRNA, Long NoncodingTransfectionTumor Suppressor Protein p53long non-coding RNA CDR1AS, humanMDM2 protein, humanProto-Oncogene Proteins c-mdm2RNA, CircularRNA, Long NoncodingTP53 protein, humanTumor Suppressor Protein p53CDR1asDNA damageGliomaMDM2p53

Identifiers

PMID32894144
PMCPMC7487905
OpenAlexW3083725797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.